



HAL
open science

Cytoplasmic and Nuclear Functions of cIAP1

Aymeric Zadoroznyj, Laurence Dubrez

► **To cite this version:**

Aymeric Zadoroznyj, Laurence Dubrez. Cytoplasmic and Nuclear Functions of cIAP1. *Biomolecules*, 2022, 12 (2), pp.322. 10.3390/biom12020322 . hal-03707070

HAL Id: hal-03707070

<https://hal.science/hal-03707070>

Submitted on 28 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cytoplasmic and nuclear functions of cIAP1

Aymeric Zadorojnyj^{1,2}, and Laurence Dubrez^{1,2,*}

¹ Inserm LNC UMR1231, LabEx LipSTIC, Dijon, France; aymeric_zadoroznyj@etu.u-bourgogne.fr ; laurence.dubrez@u-bourgogne.fr

² University of Burgundy, Dijon, France

* Correspondence: laurence.dubrez@u-bourgogne.fr

Abstract: Cellular inhibitor of apoptosis 1 (cIAP1) is a cell signaling regulator of IAP family. Through its E3-ubiquitin ligase activity, it has the ability to activate intracellular signaling pathways, modify signal transduction pathway by changing protein-protein interaction networks and stop signal transduction by promoting degradation of critical components of signaling pathways. Thus, cIAP1 appears as potent determinant of the response of cells, enabling their rapid adaptation to changing environmental conditions or to intra- or extracellular stresses. It is expressed in almost all tissues, found in the cytoplasm, membrane and/or nucleus of cells. cIAP1 regulates innate immunity by controlling signaling pathways mediated by tumor necrosis factor receptor superfamily (TNFRs), some cytokine receptors and pattern recognition-receptors (PRRs). Although less documented, cIAP1 has also been involved in the regulation of cell migration and in the control of transcriptional program.

Keywords: IAPs; signaling pathways; innate immunity, Ubiquitination, TNF α , NF- κ B, cell migration, E2F1.

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. *Biomolecules* **2021**, *11*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Lastname

Received: date
Accepted: date
Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

IAPs (Inhibitors of Apoptosis) form a family of proteins highly conserved during evolution. The named "IAP" was chosen by Lois Miller's teams who described a new class of proteins encoded by *Cydia pomonella granulosis virus* (CpGV) genome and able to protect infected-insect cells from apoptosis to allow viral spread [1]. Since then, based on sequence homologies, IAP homologs have been identified in insects, yeasts, nematodes, fishes and mammals. However, although they are able to inhibit or delay cell death when overexpressed, the main cellular function for most of them is not an inhibition of apoptosis. Among the eight described mammal homologs, XIAP (X-linked IAP)[2], cIAP1 (cellular IAP1), cIAP2, ML-IAP (Melanoma IAP) [3] and ILP-2 (IAP-like protein 2) [4] are enzymes of the ubiquitination reaction involved in proteostasis and the regulation of the assembly of intracellular signaling platforms.

XIAP has the greatest ability to inhibit apoptosis by directly interacting with initiator and effector caspases and blocking their activity [5-7]. Upon apoptotic stimuli, XIAP is neutralized by Smac (Second mitochondria derived activator of caspase) which is contained into the mitochondrial intermembrane space and released into the cytosol during the early phase of apoptotic intrinsic pathway[8-10]. Based on these observations, Smac mimetics have been developed in order to counteract the anti-apoptotic activity of IAPs in tumors. However, Smac as well as Smac mimetics are also able to bind and neutralize other IAPs such as cIAP1, cIAP2 and ML-IAP with high affinities[11].

cIAP1 and its paralogous cIAP2 are most studied for their ability to regulate innate immunity and inflammation [12]. By controlling the scaffolding and kinase activities of

RIPK1, cIAPs dictate the response of cells to tumor necrosis factor receptor (TNFR) super-family stimulation [13]. They have also been involved in the control of the inflammatory response mediated by Pattern recognition (PRRs) and cytokine receptors[14]. In addition, cIAP1 can control intracellular signaling pathways that drive cell motility and migration, regulate cell cycle cell proliferation and transcriptional programs[15].

The expression of cIAP1, cIAP2 and XIAP is preferentially induced under stressful conditions such as hypoxia, endoplasmic reticular stress and DNA damage. Regulation can occur at a transcriptional level via HIF-1 α , NF- κ B or E2F1-dependent mechanisms[16,17] or at translational level due to the presence of an internal ribosome entry site (IRES)-dependent mechanism of translation initiation[18-20]. Moreover, the stability of cIAPs is regulated by heat shock proteins (HSPs)[21]. Thus, these pleiotropic proteins appeared to act as potent regulators of the adaptive response of cells to a changing environment or in response to environmental or intracellular stresses such as pathogen attack, hypoxic-ischemic injury, or DNA damage [22]. Consistent with their role in regulating homeostasis, dysregulations of cIAPs have been observed in cancer, neurodegenerative disorders and inflammatory diseases. Moreover, the oncogenic properties of cIAP1 were clearly demonstrated in mouse models of hepatocarcinoma, osteosarcoma and breast cancer [23-25]. This review aims to analyse the role of cIAP1 and by comparison cIAP2 and XIAP in maintaining cellular homeostasis.

2. cIAP1 structure and molecular function

Belonging to IAP family is defined by structural feature *e.i.* the presence of at least one conserved protein domain named BIR (Baculoviral IAP repeat). cIAP1, cIAP2 and XIAP own 3 copies of BIRs (Figure 1). These domains have approximately 70-80 amino-acid organized into 3 short β -strands and 4-5 α -helices, forming a hydrophobic groove with protein-protein interacting properties [26]. The BIR1 of cIAP1/2 binds the signaling adaptor tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2)(Figure 1) which regulates the stability, localization and activity of the concerned IAPs and which acts as an intermediate for their recruitment into TNFR-associated signaling complex [27-29]. The BIR2 and 3 of cIAPs and XIAP have the particularity of having a deep hydrophobic pocket which allows the specific anchoring of a conserved tetrapeptide motif called IBM (IAP binding motif). The best characterized IBM-containing proteins are critical regulators of apoptosis Smac/diablo and HtrA2. cIAPs can also bind some caspases, the DNA damage response and cell cycle regulators chk1 and cdc20, eRF3/GSTP releasing factor and the kinase NIK in an IBM-dependent manner [15].

The second domain shared by cIAP1, cIAP2 and XIAP is the conserved Ring that gives them their molecular function. It is the widespread active domain found in E3-ligases of the ubiquitination reaction[30]. This is a 3-step enzymatic reaction that catalyzes the covalent binding of molecules or chains of ubiquitins of different topologies to protein substrates. This post-translational modification modifies the stability, localization, activity or the recruitment of intracellular proteins into signaling platforms, depending of the type of ubiquitin chains conjugated. Ubiquitination uses E1-activating, E2-conjugating and E3-ligase enzymes sequentially. It is generally admitted that the E3 is responsible for the recruitment of substrate proteins whereas the E2 determines the type of ubiquitination. IAPs bind, via the Ring, ubiquitin-charged E2-conjugating enzyme and catalyzes the transfer of ubiquitin moieties from the E2 to protein substrate, specifically recruited thanks to their BIR domains [15]. Like many Ring-containing E3-ligases, IAPs are active in a dimeric form [31,32]. The binding of ligand promotes their conformational change leading to activation[32]. Engagement of Smac mimetic to the BIR3-cIAP1 induces the activating dimerization and auto-ubiquitination of cIAP1 leading to its rapid degradation (within 15

minutes)[33]. We observed that cIAP1 and TRAF2 need each other to perform their respective activities. Increasing evidences suggest that they form an E3-ubiquitin ligase complex (Figure 1) in which cIAP1 functions as the E3-enzyme while TRAF2 serves as adaptor for bring cIAP1 close proximity to substrates [34,35]. TRAF2 is also potent regulator of cIAP1 stability [36,37]. In some situation, TRAF3 that directly binds TRAF2 takes part in the complex serving as the substrate binding component [34,35,38,39]. In cytokine receptor-mediated signaling pathways, TRAF2 which also harbors a Ring domain (Figure 1) can function as an E3-ligase able to promote K63-linked ubiquitination and activation of cIAP1 [34].

In addition to the BIRs and Ring, cIAPs and XIAP harbor a UBA (ubiquitin-associated) domain whose function is to bind ubiquitins [40,41] (Figure 1). It has been involved in regulating cIAPs-mediated ubiquitination. It participates in the specific recruitment of ubiquitin-charged E2 [42] and therefore in determining the type of ubiquitination [43]. cIAP-UBA has also been involved in the recruitment of cIAPs into signaling platforms and in the binding to TRAF2 [41,43]. Moreover, cIAP1 and cIAP2 have a CARD domain that regulates their activating dimerization and enzymatic activity [44]. At least, two functional NES sequences located in the BIR2-BIR3 linker region and in the CARD [45,46] were detected in cIAP1 sequence.




Figure 1. cIAP1-TRAF2 E3-Ubiquitin ligase complex, schematic representation. TRAF-N, TRAF-C, Zing finger (ZF), RING, BIRs (Baculoviral IAP repeat), UBA (ubiquitin-associated), CARD (caspase recruitment) domains and NES (Nuclear export signal) are represented. cIAP1-TRAF2 interaction involves the cIAP1-BIR1 domain and the N-terminal half of TRAF domain (TRAF-N). Trimeric TRAF2 is recruited to receptor thanks to their TRAF-C domain. Oligomerisation of TRAF2 is also required for the recruitment of downstream signaling molecules. Trimeric TRAF2 can bind one isolated BIR1.

3. Tissue expression and subcellular localisation of cIAP1 in healthy and tumor cells

As documented in the human protein atlas (Human Protein Atlas [proteinatlas.org](https://www.proteinatlas.org))[47], cIAP1 is expressed in almost all tissues and cell types tested without specificity (Figure 2, Table 1). In comparison, cIAP2 is less abundant in most tissues, except in small intestine, kidney and lymphoid tissue. cIAP2 is highly expressed in subsets of immune cells including B-cells [47]. cIAP1 has been found in the cytoplasm/membrane and/or nuclear compartments [48]. In bone marrow hematopoietic cells, ovarian follicle cells, pancreas glandular cells, squamous epithelial cells of oral mucosa and cervix, hippocampus glial cells, lung alveolar cells and testis Leydig cells [49], it was exclusively detected in the nucleus (Table 1). In a work published in 2004, we demonstrated that cIAP1 is exclusively expressed in the nucleus of hematopoietic stem cells [50] and that its trans-

location into the cytoplasm is necessary for their differentiation into macrophages or dendritic cells [21,45,50]. Such nuclear export has also been observed during epithelial differentiation [21,50].




Figure 2. Tissue distribution of cIAP1 and cIAP2 proteins (Human Protein Atlas proteinatlas.org)

Table 1. Tissue expression and subcellular localization of cIAP1 based on the human protein atlas (Human Protein Atlas proteinatlas.org)[47,48].

Organ or System	Tissue	Cells	Protein Expression	Subcellular localization ¹
Adipose tissue		Adipocytes	Medium	CMN
Central nervous system	Cerebellum	Cells in granular and molecular layer & purkinje cells	Medium	CMN
	Cerebral Cortex	Glial and neuronal cells	Medium	CM or N
	Hippocampus	Glial cells	High	N
		Neuronal cells	Medium	CM or N
	Caudate	Glial cells & Neuronal cells	Medium	CM or N
Endocrine system	Thyroid gland	Glandular cells	High	N or CM

	Parathyroid Gland	Glandular cells	Medium	CM or CMN
	Adrenal Gland	Glandular cells	High	CMN
Respiratory system	Nasopharynx	Respiratory epithelial cells	Medium	CM
	Lung	Alveolar cells	High	N
Gastrointestinal tract	Oral mucosa	Squamous epithelial cells	Medium	N
	Salivary Gland	Glandular cells	Low	CM or CMN
	Esophagus	Squamous epithelial cells	Medium	N or CMN
	Stomach	Glandular cells	Medium	CM or CMN
	Duodenum & Small intestine & colon	Glandular cells	Medium	CM or CMN
	Rectum	Glandular cells	Low	CM or CMN
Liver & Gallbladder	Liver	Cholangiocytes & hepatocytes	Medium	CM
	Gallbladder	Glandular cells	High	CMN
Pancreas		Exocrine glandular cells	Medium	N
Urinary system	Kidney	Glomeruli cells	Low to Medium	CM or N
		Tubule cells	Medium	CM or CMN
	Urinary Bladder	Urothelial cells	Medium	CMN
Female reproductive system	Vagina	Squamous epithelial cells	Low	CM or N
	Fallopian tube	Glandular cells	Medium	CM
	Endometrium	Glandular cells	Low	CMN
	Cervix	Glandular cells	Medium	CM or CMN
		Squamous epithelial cells	Low	N
	Ovary	Ovarian stromal cells	Low	CM or N
		Follicle cells	Low	N
	Placenta	Trophoblastic cells	Medium	N or CMN
Breast	Glandular & Myoepithelial cells	Low	CM	
Male reproductive system	Testis	Cells in seminiferous ducts	Low	CM
		Leydig cells	High	N
	Epididymis	Glandular cells	Medium	CM or CMN
	Seminal vesicle	Glandular cells	Medium	CMN
	Prostate	Glandular cells	Low	CM or N

Muscle tissues	Heart muscle	Cardiomyocytes	Medium	CM
	Smooth muscle	Smooth muscle cells	Low	CM
	Skeletal muscle	Myocytes	Medium	CM
Skin		Keratinocytes & Melanocytes	Low	CM
Soft tissue		Fibroblastes	Low	CM
Bone marrow & Lymphoid tissues	Appendix	Glandular cells & Lymphoid tissue	Low	CMN
	Spleen	Cells in red pulp	Low	CM or N
		Cells in chite pulp		N
	Lymph node	Germinal & non germinal center cells	Low	CM or N
	Tonsil	Germinal, non germinal center cells & squamous epithelial cells	Medium	N
	Bone marrow	Hematopoietic cells	Medium	N

¹ CM: cytoplasm/membrane; CMN: cytoplasm/membrane/nucleus; N: nucleus.

Gene expression profiling interactive analysis (GEPIA)[51] revealed that *cIAP1* expression tends to be overexpressed in 11 out of 31 tumors selected in the cancer genome atlas (TCGA), which is significant for diffuse large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM) and thymoma (THYM) (Figure 3). Nevertheless, it appears to be significantly correlated with overall survival only in lung adenocarcinoma. Conversely, *cIAP1* appeared downregulated in testicular germ cell (TGCT) and uterine cancers (UCEC) (UCS). *cIAP1* and *cIAP2*-encoding genes (named *BIRC2* and *BIRC3*) are very closely located on chromosome locus 11q22.2, a region found amplified (11q21 amplicon) in human medollublastoma, hepatic, breast, pancreatic, cervical, lung, oral squamous cell and esophageal carcinoma [52]. Conversely, multiple myeloma is associated with inactivating mutations in genes involved in non-canonical NF- κ B signaling pathway, which include *cIAP1* and/or *cIAP2*. At the protein level, *cIAP1* expression does not emerge as a cancer prognostic factor in the cancers referenced in the human protein atlas. However, its nuclear expression has been correlated with overall survival, tumor stage or poor patient prognosis in cohorts of 70 cervical cancers [53], 102 bladder cancers [54] and 55 head and neck squamous cell carcinomas [55].

171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189




Figure 3. Gene expression profile interactive analysis (GEPIA) of *birc2* (cIAP1-encoding gene) in tumors (T, red) and normal (N, grey) samples from the cancer genome atlas (TCGA) project. Only results showing a difference in *birc2* expression between cancer and normal samples are shown. CHOL: Cholangio carcinoma, DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, ESCA: Esophageal carcinoma, GBM: Glioblastoma multiforme, LAML: Acute Myeloid Leukemia, LGG: Brain Lower Grade Glioma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, STAD: Stomach adenocarcinoma, TGCT: THYM: Testicular Germ Cell Tumors, UCEC: Uterine Corpus Endometrial Carcinoma, UCS: Uterine Carcinosarcoma.

4. Cytoplasmic functions of cIAP1

4.1. Role for cIAP1 in regulating innate immunity

4.1.1. Regulation of TNF α signaling pathways in immune and non-immune cells.

The tumor necrosis factor alpha (TNF α) is the master regulator of tissue homeostasis by coordinating the inflammatory response and regulating the immune system (for review, see[56]). Dysregulated TNFR-signaling pathways or sustained production of TNF α has been involved the pathogenesis of many chronic inflammatory diseases and anti-TNF α therapy has demonstrated efficiency in the treatment of severe forms of rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Conversely, neutralizing TNF α can also result to the onset of autoimmune disease supporting its pleiotropic functions in regulating immune system [56,57]. It is produced within minutes of injury or stress, mainly by monocytes and macrophages and it exerts its activity in transmembrane or soluble, secreted forms. TNF α is endowed with multiples functions, depending on the cellular and environmental context. Its predominant activity is to trigger the production of pro-inflammatory cytokines and chemokines. It can also stimulate the survival and differentiation of immune cells, promote their recruitment to the site of damage and enhance the adhesion of endothelial cells. Under specific conditions, survival signals can switch to cell death signals. For example, TNF α can help in killing infected cells in order to contain the infection and ensure tissue integrity; it takes part to the maintenance of peripheral immune tolerance by participating to the deletion of activated T-cells [58]; it can promote the death of irreversibly damaged cells in order to ensure tissue homeostasis [56].

TNF α is recognized by TNFR1 expressed in all human tissues and by TNFR2 whose expression is limited to immune cells, neurons, endothelial cells, cardiomyocytes and osteoclast precursors. It is generally admitted that TNFR1 can trigger a strong inflammatory response and/or cell death while TNFR2 induces cell death protection and a moderate inflammation. The response to TNFR1 stimulation is orchestrated by the presence of different checkpoints. The kinase RIP1 is critical in determining the inflammatory response or cell death. It is recruited into the surface receptor-associated intracellular complex via homotypic interaction thanks to the death-domain (DD) exhibited by both the receptor (intracellular side) and RIP1[59]. In the receptor-associated signalling complex so-called complex I, RIP1 acts as a scaffold for the recruitment of kinase complexes including TAK1/TAB2/TAB3 and I κ B kinase (IKK) complex that promote MAPK and NF- κ B-mediated transcriptional programs [60] (Figure 4). This scaffolding function is fully dependent on non-degradative poly-ubiquitination including K11, K63-linked, linear and hybrid-polyubiquitination[61,62]. On the other hand, thanks to its kinase activity, RIP1 can promote the assembly of a secondary cytoplasmic complexes including complex-II, ripoptosome and necrosome that results in apoptotic or necroptotic cell death[63] (Figure 4). Necroptosis is associated with a massive release of cytokines, chemokines and damage-associated molecular patterns (DAMPs) recognized by pattern recognition receptors (PRRs) that trigger innate immune response [64,65]. The role of TNF α in chronic inflammatory diseases has been explained by its capacity of activated this immunogenic cell death [57].

cIAP1 takes part to this regulation. It constitutes an essential survival factor in intestinal epithelial cells, neutrophils, macrophages and activated T cells allowing them to resist to TNFR1-mediated cell death when exposed to an acute inflammatory environment[66-70]. Depletion of cIAPs prevents TNF α -mediated NF- κ B and MAPK activation and sensitizes cells to TNF α -mediated cell death [71-74]. In mice, deletion of cIAP1 as well as cIAP2 or XIAP did not lead to obvious phenotypic abnormalities. A moderate inflammation in lungs and intestines was observed in cIAP1^{-/-} KO mice [75]. However, double deletion of cIAP1 and cIAP2 or cIAP1 and XIAP in mice lead to embryonic lethality in TNFR1 and RIP1-dependent manner [72] and specific depletion of cIAP1, -2 and XIAP in myeloid lineage or keratinocytes causes a severe local inflammation and TNFR1 or RIPK1-dependent cell death [68,76,77]. By controlling the stability, scaffold function and kinase activity of RIP1, cIAPs have the ability to control the intensity and duration of the TNFR1-mediated inflammatory response: (i) they activate the scaffold function of RIP1 by promoting the conjugation of K11 and K63-linked poly-ubiquitin chains on components of complex I that include RIP1 [43,78-80]; they can inactivate the TNFR1-mediated signalling pathway by promotion ubiquitin-dependent degradation of RIP1 [43]; (iii) alternatively, cIAP-mediated ubiquitination of RIP1 represses its kinase activity necessary for the assembly of cell-death-mediated complexes-II [43] and then prevents TNF-mediated cytotoxicity and necroptosis-associated massive inflammation [81] (Figure 4). In addition to controlling scaffold function, kinase activity and stability of RIP1, cIAP1 can regulate the TNF α -mediated NF- κ B activating signalling pathway by ubiquitination of NEMO/IKK γ (NF- κ B essential modulator/I κ B kinase- γ) the regulatory subunit of IKK complex [82].




Figure 4. Regulation of signaling pathways by cIAP1. The cIAP1-TRAF2 E3-Ubiquitin ligase complex regulates the cellular content of NIK by mediating its ubiquitin-proteasome dependent degradation. The recruitment of cIAP1/TRAF2 to TNFR2, CD30, CD40 or BAFF-R releases NIK that in turn stimulates the non-canonical NF-κB signaling pathway. In the TLR4-associated signaling complex, cIAP1 induces the ubiquitination and degradation of TRAF3. cIAP1/TRAF2 forms a secondary cytoplasmic complex leading to NF-κB / MAPK activation. In TNFR1-associated complex, cIAP1 induces the ubiquitination of RIP1 and other components of the complex, resulting in the assembly of signaling platform driving NF-κB and MAPK activation. Ubiquitination of RIP1 by cIAP1 inhibits its kinase activity required for the assembly of cytoplasmic RIP-containing platform leading to apoptotic or necrotic cell death. cIAP1 controls the cycle of activation of cdc42. The recruitment of cIAP1/TRAF2 to TNFR-associated signaling complex releases cdc42 for activation. BAFF-R: B-cell activating factor receptor; CD40-R: cluster of differentiation 40 receptor, IKKα, β or γ: Inhibitor of κB kinase α, β or γ; LUBAC: linear ubiquitin chain assembly complex; Myd88: Myeloid differentiation primary response 88; NIK: NF-κB-inducing kinase; Rho-GDI: Rho-guanine-nucleotide dissociation inhibitors; TAB1, 2 or 3: transforming growth factor-activated kinase1-binding protein 1, 2, and 3; TAK1: tumor growth factor-β-activated kinase 1; TLR 4: toll-like receptor 4; TNFR2: tumor necrosis factor Receptor 2, TRADD: TNFR-associated death domain; TRIF: toll-interleukin 1 receptor domain-containing adaptor inducing IFN-β.

TNFR2 plays a role in promoting differentiation and stabilization of regulatory T cells and mutation in TNFR2 has been involved in the pathogenesis of several autoimmune diseases [57]. In endothelial cells, it participates in tissue regeneration. Since the TNFR2 protein does not harbour DD (death- domain), it cannot recruit RIP1 but it can directly bind the molecular adaptors TRAF2 and TRAF3. TRAF2 recruits cIAP1 into the TNFR2-associated signalling complex. As observed in the TNFR1-associated signalling complex, cIAP1 can promote K63-linked polyubiquitination at the TNFR2-signaling complex [83] resulting in the recruitment and activation of kinase complexes that drive MAPK and canonical NF-κB. However, TNFR2 stimulation likely leads to cIAPs-dependent canonical NF-κB activation [83] (see below).

270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301

4.1.2. Regulation of the non-canonical NF- κ B signalling pathway in immune cells, osteoclasts and endothelial cells.

The best characterized substrate of the cIAP1/TRAF2 E3-ubiquitin ligase complex is NF- κ B-inducing kinase (NIK), an essential mediator of the non-canonical NF- κ B signalling pathway [34,84,85].

The non-canonical NF- κ B signalling pathway is characterized by inducible processing of the p100 subunit in active p52 which, when heterodimerized with RelB, acts as transcription factor. The processing of p100 is triggered following its phosphorylation by the IKK α homodimer, itself activated by NIK [86]. cIAP1 regulates the NF- κ B alternative pathway by controlling the cellular content of NIK. In resting condition, NIK is recruited to cIAP1/TRAF2 complex via TRAF3. The complex is stabilized by direct binding of NIK with the BIR2 domain of cIAP1 in IBM-dependent manner [34,38,85]. cIAP1 promotes ubiquitin-mediated proteasomal degradation of NIK, turning off the non-canonical NF- κ B signalling pathway [34,84,85] (Figure 4). Stimulation of TNFR2, CD30, CD40, BAFF-R (B-cell-activating factor) or FN14 leads to the recruitment of TRAF2/TRAF3/cIAP1 complex to membrane-associated signalling complex [37,87-90]. TRAF2 induced cIAP1 activation via K63-linked ubiquitination. In turn, cIAP1 catalyses K43-linked ubiquitination of TRAF2/3 and their degradation by the proteasome system, resulting in upregulation of NIK and activation of non-canonical NF- κ B signalling [34].

Non-canonical NF- κ B signalling is essential for the activation, survival and differentiation of immune cells such as B-cells, macrophages and dendritic cells. Deletion of cIAP1 and cIAP2 in mice maintained B-cells survival and maturation independently of BAFF-R stimulation [88] and can account for B-cell transformation [91-93]. We demonstrated that cIAP1-mediated degradation of TRAF2 is essential for the full activity of macrophages in response to CD40 stimulation [45]. IAP antagonists can also favour osteoclasts differentiation in a NIK-dependent manner, supporting the critical role of the non-canonical NF- κ B signalling pathway in osteoclastogenesis [94].

4.1.3. Regulation of PRR signalling pathways.

The presence of pathogens in organisms is sensed by cell surface and intracellular receptors able to recognize a wide variety of pathogen-associated molecular patterns (PAMPs) and danger signal (DAMPs). Among them, the cell surface membrane TLR4 which recognizes bacteria lipopolysaccharides (LPS) can elicit distinct signalling pathways leading to either pro-inflammatory or interferon response. TLR4 engagement induces the recruitment of several cytoplasmic adaptor proteins thanks to the presence, in both the receptors and adaptors, of a homotypic interacting domain. The adaptor MyD88 (myeloid differentiation factor 88) has been involved in NF- κ B and MAPK-dependent production of pro-inflammatory cytokines whereas the adaptor TRIF (TIR-domain-containing adaptor-inducing IFN- β) is required for the IFN response. The cIAP1/TRAF2 E3-ubiquitin ligase complex is a potent determinant of the response to TLR4 stimulation. MyD-88 can directly recruit the adaptor TRAF3 which can bind TRAF2/cIAP1 complex. In the MyD88-containing TLR4 complex (so-called MyDosome), the cIAP1/TRAF2 E3-ubiquitin ligase complex induces the ubiquitination and degradation of TRAF3 which results in the assembly of a secondary cytoplasmic signalling platform containing TRAF2/cIAP1, TAK1/TAB1-3 and IKK complexes leading to the activation of MAPK (Mitogen-activated protein kinases) and NF- κ B (nuclear factor-kappa B)-signaling pathways [95-97] (Figure 4). Depletion of TRAF3 can also turn-off the IFN response that involved the TRAF6/TRAF3 complex.

In some situations, such as a sustained infection, the presence of pathogens resistant to inflammatory defence or in some pathological conditions, TLR4, just like TLR3 which senses virus-derived nucleic acids, can also trigger RIP1-dependent cell death

through a direct binding of RIP1 to the adaptor TRIF. cIAP1 constitutes a powerful survival factor in infected cells by preventing the assembly of ripoptosome and necrosome as explained above (4.1.1) [65,77].

Supporting the role of IAPs in controlling the strength and duration of the inflammatory response, Jin *et al.* showed that the cIAP1/TRAF2 complex can limit inflammation by promoting the ubiquitin-proteasome dependent degradation of c-Rel and IRF5 (interferon-responsive factor 5), two critical transcription factors involved in TLR-mediated NF- κ B-dependent inflammatory and IFN response respectively. Depletion of TRAF2 in macrophages promoted colitis characterized by enhanced leukocyte infiltration in colon, mucosal damage and pro-inflammatory cytokines production in an animal model [35].

4.2. Role for cIAP1 in cell motility and migration

Cell shape and cell motility are controlled by small GTPases of Rho family. These proteins are critical regulators of the dynamic reorganization of the actin cytoskeleton [98-100]. They control cell architecture, focal adhesion complexes and local contraction by promoting the generation of stress fibers or membrane protrusions such as lamellopodia or filopodia [101]. They switch between a cytoplasmic, inactive GDP-bound state and a membrane-associated, active GTP-bound state, providing energy required for cytoskeleton rearrangement. RhoGTPase activation is mediated by guanine-nucleotide exchange factors (GEFs), which catalyze the transfer of GDP-bound to GTP-bound forms. Once activated, RhoGTPases are either recycled in inactive state by action of GTPase-activation proteins (GAPs) or subjected to UPS-mediated degradation. The activation cycle of Rho GTPase is controlled by molecular chaperones such as guanine-nucleotide dissociation inhibitors (GDIs) which stabilize Rho GTPases in their cytosolic inactive state [101]. A relationship between IAPs and RhoGTPases was suggested in 2004 in a study showing that drosophila DIAP1 can interact with Rac1 and compensate for the migration defect triggered by the expression of a dominant negative form of this GTPase [102]. In mammals, *in vitro* assays have demonstrated that cIAP1, cIAP2 and XIAP are able to directly interact with the three most studied RhoGTPases [103-106] RhoA, Rac1 and cdc42 which promote lamellopodia, stress fibers or filopodia respectively. In a study analysing the influence of cIAP1 on cell shape and migration, we demonstrated that cIAP1 can directly bind cdc42. It stabilizes cdc42 in its GDP-, inactive-state by promoting its association with its molecular chaperone RhoGDI. Deletion of cIAP1 deregulated the activation cycle of cdc42 by promoting its activation and then degradation [103]. Accordingly, cIAP1^{-/-} fibroblasts display an enhanced ability to migrate and exhibit filopodia. TNF α has the ability to induce cdc42 activation and actin reorganisation [99,100]. Upon TNF α stimulation, cIAP1 is recruited to the membrane receptor-associated complex, releasing cdc42 and promoting its activation [103](Figure 4). The ubiquitination of cdc42 by cIAP1 has not been demonstrated, however, the ability of XIAP to ubiquitinate cdc42 and of XIAP and cIAP1 to ubiquitinate Rac1 has been observed [104,107]. Single or combined deletion of cIAP1, cIAP2 or XIAP differently affects cell shape, actin distribution and migratory capacity. They appear to have specific and distinct activity on each of the Rho proteins suggesting that IAPs could regulate the spatiotemporal and sequential activation of Rho proteins [108]. Additional analysis will be required to decipher the regulation of the Rho proteins by IAPs.

5. Nuclear functions of cIAP1

cIAP1 is a nuclear shuttling protein. Its nuclear expression has been correlated with the proliferative capacity of the cells. cIAP1 is excluded from the nucleus in cells undergoing differentiation [50]. Nuclear export is supported by the nuclear transport receptor Crm1 (chromosome region maintenance 1) which specifically recognizes leucine-rich

nuclease export sequences (NES). Two NES were detected in the cIAP1 protein sequence, the first is located in the linked region between the BIR2 and the BIR3 [46] and the second in the CARD domain [50]. Since the cIAP1 protein does not contain a NLS, one important issue is understanding the mechanisms of its nuclear accumulation. In the nucleus of B-cell, cIAP1 is complexed with TRAF2 and TRAF3, the latter containing a functional NLS in its TRAF-C domain [39]. We demonstrated that cIAP1 engages with chromatin. Different transcription factors are ubiquitination substrate of cIAP1. In 2011, the research of nuclear partners of cIAP1 revealed its binding with the transcription factor E2F1 [109]. This involves the cIAP1-BIR3 domain [17]. Deletion of cIAP1 completely abrogated the recruitment of the transcription factor onto DNA [17]. We demonstrated that cIAP1-E2F1 are recruited together to the promoter of E2F-target genes in S phase of the cell cycle [109]. Nuclear cIAP1 can promote K11- and K63-linked ubiquitination of E2F1 [17] and stabilize its protein expression. cIAP1-mediated K63-ubiquitination at Lysine 161/163 residues of E2F1 is required for its accumulation and transcriptional activation in S phase of cell cycle and in response to DNA damage [110].

As mentioned above, cIAP1/TRAF2 E3-ubiquitin ligase complex is able to promote ubiquitination and degradation of the transcription factors c-Rel and IRF5 [35] and also cAMP response element binding protein CREB [39]. The degradation of CREB in B-cells occurs in the nucleus and involves TRAF3 which bridges CREB to the E3-ubiquitin ligase complex [39]. Interestingly, CD40L stimulation in neurons has been observed to induce the translocation of TRAF2/TRAF3 complex into the nucleus where it can bind NF- κ B promoter element and act as a transcriptional regulator [111]. The presence of cIAP1 in the complex has not been analyzed.

Nuclear cIAP1 can also promote the neddylation and degradation of p21 involved in the transition into G2/M phase of cell cycle[112] and it can interact with the transcriptional cofactors Vestigial-like 4 (Vgl-4)[113] and C-terminal binding protein 2 (CtBP2) [114].

6. Conclusions

cIAP1 mainly exerts its activity by controlling cell fate of its protein partners. Thanks to their ability to promote the conjugation of ubiquitin chains of different types, they can modulate the stability, localization and/or the activity of intracellular proteins and they can change the composition of signalling platforms by modifying the intermolecular binding affinities. Thus, IAPs have the ability to control the implementation of signalling pathways and their regulations in time and space. Up to date, more than 30 cIAP substrates have been identified (recently reviewed in[15]). A database search for proteins containing IBM-like sequence found many proteins with different cellular functions [115], greatly expanding the number of potential IAP-binding partners. The identified IAP substrates are involved in various cellular processes essential for maintaining cell homeostasis (innate immune response, DNA damage response, cell cycle regulation...). For most of them, the type and site of ubiquitination have not been determined. However, this is an important issue to address since they determine the cellular fate of the substrate[43].

The ultimate function of IAPs is to allow cells to adapt to their changing environment, to help at the implement of an appropriate response to combat endogenous or exogenous stress or microbial aggression and to restore homeostasis. Although loss of cIAPs in mice has been associated with locale inflammation in lung, intestines or skin [75,76], deletion or mutation of BIRC2/3 gene have not been associated with chronic inflammatory disease but cancer development. A more in-depth studies of the implication of cIAPs in these pathologies deserve to be carried out.

The expression of cIAP1 is ubiquitous and its regulation mechanisms are still poorly understood. The last observations suggest that cIAP1 and TRAF2 require each other and form an E3-ubiquitin ligase complex. cIAP1 E3-ligase activity is stimulated by K63-linked

ubiquitination that can be mediated by TRAF2 or TRAF6 [34,95]. The stability of cIAP1 can be controlled by phosphorylation[116] and its regulation by S-nitrosylation, oxidation processes have also been reported [117,118].

Smac mimetics designed to block XIAP anti-apoptotic activity are also potent inhibitors of cIAP1. They have been developed as anticancer agents. However, because of the ability of cIAP1 to regulate RIP1 activities, numerous preclinical studies are exploring their potential in the treatment of inflammatory and infectious diseases.

Funding: Our work is supported by grants from “La Ligue contre le cancer” Comité de la Côte d’Or », the “Conseil Regional de Bourgogne-Franche-Comté”, the French National research Agency, (“Investissements d’Avenir” program ANR-11-LABX-0021), the European Union program FEDER, and fellowships from the “Ministere de l’Enseignement Supérieur et de la Recherche” of France (AZ).

Data Availability Statement: We use the human protein atlas (Human Protein Atlas proteinatlas.org), Gene expression profiling interactive analysis (GEPIA) (<http://gepia.cancer-pku.cn/>) and the cancer genome atlas (TCGA) to analyze the cellular and tissue distribution of IAPs

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Crook, N.E.; Clem, R.J.; Miller, L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J Virol* **1993**, *67*, 2168-2174, doi:10.1128/JVI.67.4.2168-2174.1993.
2. Liston, P.; Roy, N.; Tamai, K.; Lefebvre, C.; Baird, S.; Cherton-Horvat, G.; Farahani, R.; McLean, M.; Ikeda, J.E.; MacKenzie, A.; et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature* **1996**, *379*, 349-353, doi:10.1038/379349a0.
3. Vucic, D.; Stennicke, H.R.; Pisabarro, M.T.; Salvesen, G.S.; Dixit, V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol* **2000**, *10*, 1359-1366, doi:S0960-9822(00)00781-8 [pii].
4. Vucic, D.; Kaiser, W.J.; Harvey, A.J.; Miller, L.K. Inhibition of reaper-induced apoptosis by interaction with inhibitor of apoptosis proteins (IAPs). *Proc Natl Acad Sci U S A* **1997**, *94*, 10183-10188.
5. Deveraux, Q.L.; Takahashi, R.; Salvesen, G.S.; Reed, J.C. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature* **1997**, *388*, 300-304, doi:10.1038/40901.
6. Takahashi, R.; Deveraux, Q.; Tamm, I.; Welsh, K.; Assa-Munt, N.; Salvesen, G.S.; Reed, J.C. A single BIR domain of XIAP sufficient for inhibiting caspases. *J Biol Chem* **1998**, *273*, 7787-7790.
7. Chai, J.; Shiozaki, E.; Srinivasula, S.M.; Wu, Q.; Datta, P.; Alnemri, E.S.; Shi, Y. Structural basis of caspase-7 inhibition by XIAP. *Cell* **2001**, *104*, 769-780.
8. Chai, J.; Du, C.; Wu, J.W.; Kyin, S.; Wang, X.; Shi, Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* **2000**, *406*, 855-862, doi:10.1038/35022514.
9. Hegde, R.; Srinivasula, S.M.; Zhang, Z.; Wassell, R.; Mukattash, R.; Cilenti, L.; DuBois, G.; Lazebnik, Y.; Zervos, A.S.; Fernandes-Alnemri, T.; et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. *The Journal of biological chemistry* **2002**, *277*, 432-438, doi:10.1074/jbc.M109721200.
10. Verhagen, A.M.; Silke, J.; Ekert, P.G.; Pakusch, M.; Kaufmann, H.; Connolly, L.M.; Day, C.L.; Tikoo, A.; Burke, R.; Wrobel, C.; et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. *The Journal of biological chemistry* **2002**, *277*, 445-454, doi:10.1074/jbc.M109891200.
11. Morrish, E.; Brumatti, G.; Silke, J. Future Therapeutic Directions for Smac-Mimetics. *Cells* **2020**, *9*, doi:10.3390/cells9020406.

12. Uren, A.G.; Pakusch, M.; Hawkins, C.J.; Puls, K.L.; Vaux, D.L. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. *Proc Natl Acad Sci U S A* **1996**, *93*, 4974-4978. 497-499
13. Peltzer, N.; Darding, M.; Walczak, H. Holding RIPK1 on the Ubiquitin Leash in TNFR1 Signaling. *Trends Cell Biol* **2016**, *26*, 445-461, doi:10.1016/j.tcb.2016.01.006. 500-501
14. Estornes, Y.; Bertrand, M.J. IAPs, regulators of innate immunity and inflammation. *Semin Cell Dev Biol* **2015**, *39*, 106-114, doi:10.1016/j.semcdb.2014.03.035. 502-503
15. Dumetier, B.; Zadoroznyj, A.; Dubrez, L. IAP-Mediated Protein Ubiquitination in Regulating Cell Signaling. *Cells* **2020**, *9*, doi:10.3390/cells9051118. 504-505
16. Wang, D.; Berglund, A.E.; Kenchappa, R.S.; MacAulay, R.J.; Mulé, J.J.; Etame, A.B. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats. *Sci Rep* **2017**, *7*, 9350, doi:10.1038/s41598-017-09503-8. 506-508
17. Allègre, J.; Cartier, J.; Glorian, V.; Droin, N.; Dumetier, B.; Kayaci, C.; Berthelet, J.; Gemble, S.; Vuillier, C.; Maillet, L.; et al. E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding. *PLoS One* **2018**, *13*, e0206253, doi:10.1371/journal.pone.0206253. 509-511
18. Warnakulasuriyarachchi, D.; Cerquozzi, S.; Cheung, H.H.; Holcik, M. Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. *J Biol Chem* **2004**, *279*, 17148-17157. 512-514
19. Riley, A.; Jordan, L.E.; Holcik, M. Distinct 5' UTRs regulate XIAP expression under normal growth conditions and during cellular stress. *Nucleic Acids Res* **2010**, *38*, 4665-4674, doi:10.1093/nar/gkq241. 515-516
20. Van Eden, M.E.; Byrd, M.P.; Sherrill, K.W.; Lloyd, R.E. Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress. *RNA* **2004**, *10*, 469-481. 517-518
21. Didelot, C.; Lanneau, D.; Brunet, M.; Bouchot, A.; Cartier, J.; Jacquél, A.; Ducoroy, P.; Cathelin, S.; Decolonne, N.; Chiosis, G.; et al. Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. *Cell Death Differ* **2008**, *15*, 859-866. 519-521
22. Marivin, A.; Berthelet, J.; Plenchette, S.; Dubrez, L. The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular Stress. *Cells* **2012**, *1*, 711-737, doi:10.3390/cells1040711. 522-523
23. Zender, L.; Spector, M.S.; Xue, W.; Flemming, P.; Cordon-Cardo, C.; Silke, J.; Fan, S.T.; Luk, J.M.; Wigler, M.; Hannon, G.J.; et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell* **2006**, *125*, 1253-1267. 524-526
24. Ma, O.; Cai, W.W.; Zender, L.; Dayaram, T.; Shen, J.; Herron, A.J.; Lowe, S.W.; Man, T.K.; Lau, C.C.; Donehower, L.A. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. *Cancer Res* **2009**, *69*, 2559-2567. 527-529
25. Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I.A.; Wang, W.; Camps, J.; Ried, T.; Nikitin, A.Y. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. *Oncogene* **2010**, *29*, 5700-5711, doi:10.1038/onc.2010.300. 530-532
26. Budhidarmo, R.; Day, C.L. IAPs: Modular regulators of cell signalling. *Seminars in cell & developmental biology* **2015**, *39*, 80-90, doi:10.1016/j.semcdb.2014.12.002. 533-534
27. Samuel, T.; Welsh, K.; Lober, T.; Togo, S.H.; Zapata, J.M.; Reed, J.C. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. *J Biol Chem* **2006**, *281*, 1080-1090. 535-537

28. Zheng, C.; Kabaleeswaran, V.; Wang, Y.; Cheng, G.; Wu, H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. *Mol Cell* **2010**, *38*, 101-113, doi:10.1016/j.molcel.2010.03.009. 538
539
29. Mace, P.D.; Smits, C.; Vaux, D.L.; Silke, J.; Day, C.L. Asymmetric recruitment of cIAPs by TRAF2. *J Mol Biol* **2010**, *400*, 8-15, doi:S0022-2836(10)00443-2 [pii] 10.1016/j.jmb.2010.04.055. 540
541
30. Zheng, N.; Shabek, N. Ubiquitin Ligases: Structure, Function, and Regulation. *Annu Rev Biochem* **2017**, *86*, 129-157, doi:10.1146/annurev-biochem-060815-014922. 542
543
31. Nakatani, Y.; Kleffmann, T.; Linke, K.; Condon, S.M.; Hinds, M.G.; Day, C.L. Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase. *The Biochemical journal* **2013**, *450*, 629-638, doi:10.1042/bj20121702. 544
545
32. Phillips, A.H.; Schoeffler, A.J.; Matsui, T.; Weiss, T.M.; Blankenship, J.W.; Zobel, K.; Giannetti, A.M.; Dueber, E.C.; Fairbrother, W.J. Internal motions prime cIAP1 for rapid activation. *Nat Struct Mol Biol* **2014**, *21*, 1068-1074, doi:10.1038/nsmb.2916. 546
548
33. Dueber, E.C.; Schoeffler, A.J.; Lingel, A.; Elliott, J.M.; Fedorova, A.V.; Giannetti, A.M.; Zobel, K.; Maurer, B.; Varfolomeev, E.; Wu, P.; et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. *Science* **2011**, *334*, 376-380, doi:10.1126/science.1207862. 549
550
551
34. Vallabhapurapu, S.; Matsuzawa, A.; Zhang, W.; Tseng, P.H.; Keats, J.J.; Wang, H.; Vignali, D.A.; Bergsagel, P.L.; Karin, M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. *Nat Immunol* **2008**, *9*, 1364-1370, doi:ni.1678 [pii] 10.1038/ni.1678. 552
553
554
35. Jin, J.; Xiao, Y.; Hu, H.; Zou, Q.; Li, Y.; Gao, Y.; Ge, W.; Cheng, X.; Sun, S.C. Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages. *Nat Commun* **2015**, *6*, 5930, doi:10.1038/ncomms6930. 555
556
36. Csomos, R.A.; Brady, G.F.; Duckett, C.S. Enhanced cytoprotective effects of the inhibitor of apoptosis protein cellular IAP1 through stabilization with TRAF2. *J Biol Chem* **2009**, *284*, 20531-20539, doi:10.1074/jbc.M109.029983. 557
558
37. Csomos, R.A.; Wright, C.W.; Galban, S.; Oetjen, K.A.; Duckett, C.S. Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation. *Biochem J* **2009**, *420*, 83-91. 559
560
38. Lee, S.; Challa-Malladi, M.; Bratton, S.B.; Wright, C.W. Nuclear factor-kappaB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1). *J Biol Chem* **2014**, *289*, 30680-30689, doi:10.1074/jbc.M114.587808. 561
562
563
39. Mambetsariev, N.; Lin, W.W.; Stunz, L.L.; Hanson, B.M.; Hildebrand, J.M.; Bishop, G.A. Nuclear TRAF3 is a negative regulator of CREB in B cells. *Proc Natl Acad Sci U S A* **2016**, *113*, 1032-1037, doi:10.1073/pnas.1514586113. 564
565
40. Blankenship, J.W.; Varfolomeev, E.; Goncharov, T.; Fedorova, A.V.; Kirkpatrick, D.S.; Izrael-Tomasevic, A.; Phu, L.; Arnott, D.; Aghajani, M.; Zobel, K.; et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). *Biochem J* **2009**, *417*, 149-160. 566
567
568
41. Gyrd-Hansen, M.; Darding, M.; Miasari, M.; Santoro, M.M.; Zender, L.; Xue, W.; Tenev, T.; da Fonseca, P.C.; Zvelebil, M.; Bujnicki, J.M.; et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. *Nat Cell Biol* **2008**, *10*, 1309-1317. 569
570
571
42. Budhidarmo, R.; Day, C.L. The ubiquitin-associated domain of cellular inhibitor of apoptosis proteins facilitates ubiquitylation. *The Journal of biological chemistry* **2014**, *289*, 25721-25736, doi:10.1074/jbc.M113.545475. 572
573
43. Annibaldi, A.; Wicky John, S.; Vanden Berghe, T.; Swatek, K.N.; Ruan, J.; Liccardi, G.; Bianchi, K.; Elliott, P.R.; Choi, S.M.; Van Coillie, S.; et al. Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2. *Mol Cell* **2018**, *69*, 566-580.e565, doi:10.1016/j.molcel.2018.01.027. 574
575
576
44. Lopez, J.; John, S.W.; Tenev, T.; Rautureau, G.J.; Hinds, M.G.; Francalanci, F.; Wilson, R.; Broemer, M.; Santoro, M.M.; Day, C.L.; et al. CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. *Molecular cell* **2011**, *42*, 569-583, doi:10.1016/j.molcel.2011.04.008. 577
578
579

45. Dupoux, A.; Cartier, J.; Cathelin, S.; Filomenko, R.; Solary, E.; Dubrez-Daloz, L. cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand. *Blood* **2009**, *113*, 175-185. 580
581
46. Vischioni, B.; Giaccone, G.; Span, S.W.; Kruyt, F.A.; Rodriguez, J.A. Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. *Exp Cell Res* **2004**, *298*, 535-548. 582
583
47. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. *Science* **2015**, *347*, 1260419, doi:10.1126/science.1260419. 584
585
586
48. Thul, P.J.; Åkesson, L.; Wiking, M.; Mahdessian, D.; Geladaki, A.; Ait Blal, H.; Alm, T.; Asplund, A.; Björk, L.; Breckels, L.M.; et al. A subcellular map of the human proteome. *Science* **2017**, *356*, doi:10.1126/science.aal3321. 587
588
49. Wang, Y.; Suominen, J.S.; Parvinen, M.; Rivero-Muller, A.; Kiiveri, S.; Heikinheimo, M.; Robbins, I.; Toppari, J. The regulated expression of c-IAP1 and c-IAP2 during the rat seminiferous epithelial cycle plays a role in the protection of germ cells from Fas-mediated apoptosis. *Mol Cell Endocrinol* **2005**, *245*, 111-120, doi:10.1016/j.mce.2005.11.004. 589
590
591
50. Plenchette, S.; Cathelin, S.; Rebe, C.; Launay, S.; Ladoire, S.; Sordet, O.; Ponnelle, T.; Debili, N.; Phan, T.H.; Padua, R.A.; et al. Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. *Blood* **2004**, *104*, 2035-2043, doi:10.1182/blood-2004-01-0065 2004-01-0065 [pii]. 592
593
594
595
51. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Zhang, Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* **2017**, *45*, W98-W102, doi:10.1093/nar/gkx247. 596
597
52. Dubrez, L.; Berthelet, J.; Glorian, V. IAP proteins as targets for drug development in oncology. *OncoTargets and therapy* **2013**, *9*, 1285-1304, doi:10.2147/ott.s33375. 598
599
53. Imoto, I.; Tsuda, H.; Hirasawa, A.; Miura, M.; Sakamoto, M.; Hirohashi, S.; Inazawa, J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. *Cancer Res* **2002**, *62*, 4860-4866. 600
601
54. Che, X.; Yang, D.; Zong, H.; Wang, J.; Li, X.; Chen, F.; Chen, X.; Song, X. Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients. *Urol Oncol* **2012**, *30*, 450-456, doi:10.1016/j.urolonc.2010.12.016 S1078-1439(10)00403-5 [pii]. 602
603
604
55. Tanimoto, T.; Tsuda, H.; Imazeki, N.; Ohno, Y.; Imoto, I.; Inazawa, J.; Matsubara, O. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. *Cancer Lett* **2005**, *224*, 141-151. 605
606
607
56. Holbrook, J.; Lara-Reyna, S.; Jarosz-Griffiths, H.; McDermott, M. Tumour necrosis factor signalling in health and disease. *F1000Res* **2019**, *8*, doi:10.12688/f1000research.17023.1. 608
609
57. Tseng, W.Y.; Huang, Y.S.; Lin, H.H.; Luo, S.F.; McCann, F.; McNamee, K.; Clanchy, F.; Williams, R. TNFR signalling and its clinical implications. *Cytokine* **2018**, *101*, 19-25, doi:10.1016/j.cyto.2016.08.027. 610
611
58. Zhang, M.; Wang, J.; Jia, L.; Huang, J.; He, C.; Hu, F.; Yuan, L.; Wang, G.; Yu, M.; Li, Z. Transmembrane TNF- α promotes activation-induced cell death by forward and reverse signaling. *Oncotarget* **2017**, *8*, 63799-63812, doi:10.18632/oncotarget.19124. 612
613
614
59. He, S.; Wang, X. RIP kinases as modulators of inflammation and immunity. *Nat Immunol* **2018**, *19*, 912-922, doi:10.1038/s41590-018-0188-x. 615
616
60. Annibaldi, A.; Meier, P. Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer. *Trends Mol Med* **2018**, *24*, 49-65, doi:10.1016/j.molmed.2017.11.002. 617
618
61. Emmerich, C.H.; Bakshi, S.; Kelsall, I.R.; Ortiz-Guerrero, J.; Shpiro, N.; Cohen, P. Lys63/Met1-hybrid ubiquitin chains are commonly formed during the activation of innate immune signalling. *Biochem Biophys Res Commun* **2016**, *474*, 452-461, doi:10.1016/j.bbrc.2016.04.141. 619
620
621

62. Witt, A.; Vucic, D. Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. *Cell Death Differ* **2017**, *24*, 1160-1171, doi:10.1038/cdd.2017.33. 622
623
63. Schwarzer, R.; Laurien, L.; Pasparakis, M. New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8. *Curr Opin Cell Biol* **2020**, *63*, 186-193, doi:10.1016/j.ceb.2020.02.004. 624
625
64. Frank, D.; Vince, J.E. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. *Cell Death Differ* **2019**, *26*, 99-114, doi:10.1038/s41418-018-0212-6. 626
627
65. Lawlor, K.E.; Khan, N.; Mildenhall, A.; Gerlic, M.; Croker, B.A.; D'Cruz, A.A.; Hall, C.; Kaur Spall, S.; Anderton, H.; Masters, S.L.; et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. *Nat Commun* **2015**, *6*, 6282, doi:10.1038/ncomms7282. 628
629
630
66. Chen, K.W.; Lawlor, K.E.; von Pein, J.B.; Boucher, D.; Gerlic, M.; Croker, B.A.; Bezbradica, J.S.; Vince, J.E.; Schroder, K. Cutting Edge: Blockade of Inhibitor of Apoptosis Proteins Sensitizes Neutrophils to TNF- but Not Lipopolysaccharide-Mediated Cell Death and IL-1 β Secretion. *J Immunol* **2018**, *200*, 3341-3346, doi:10.4049/jimmunol.1701620. 631
632
633
67. Grabinger, T.; Bode, K.J.; Demgenski, J.; Seitz, C.; Delgado, M.E.; Kostadinova, F.; Reinhold, C.; Etemadi, N.; Wilhelm, S.; Schweinlin, M.; et al. Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells. *Gastroenterology* **2017**, *152*, 867-879, doi:10.1053/j.gastro.2016.11.019. 634
635
636
68. Wong, W.W.; Vince, J.E.; Lalaoui, N.; Lawlor, K.E.; Chau, D.; Bankovacki, A.; Anderton, H.; Metcalf, D.; O'Reilly, L.; Jost, P.J.; et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. *Blood* **2014**, *123*, 2562-2572, doi:10.1182/blood-2013-06-510743. 637
638
639
69. Liu, H.; Liao, R.; He, K.; Zhu, X.; Li, P.; Gong, J. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells. *Immunol Lett* **2017**, *185*, 79-83, doi:10.1016/j.imlet.2017.02.016. 640
641
642
70. Gentle, I.E.; Moelter, I.; Lechler, N.; Bambach, S.; Vucikujia, S.; Häcker, G.; Aichele, P. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. *Blood* **2014**, *123*, 659-668, doi:10.1182/blood-2013-01-479543. 643
644
645
71. Varfolomeev, E.; Goncharov, T.; Fedorova, A.V.; Dynek, J.N.; Zobel, K.; Deshayes, K.; Fairbrother, W.J.; Vucic, D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNF α)-induced NF- κ B activation. *J Biol Chem* **2008**, *283*, 24295-24299. 646
647
648
72. Moulin, M.; Anderton, H.; Voss, A.K.; Thomas, T.; Wong, W.W.; Bankovacki, A.; Feltham, R.; Chau, D.; Cook, W.D.; Silke, J.; et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. *The EMBO journal* **2012**, *31*, 1679-1691, doi:10.1038/emboj.2012.18. 649
650
651
73. Feoktistova, M.; Geserick, P.; Kellert, B.; Dimitrova, D.P.; Langlais, C.; Hupe, M.; Cain, K.; MacFarlane, M.; Hacker, G.; Leverkus, M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol Cell* **2011**, *43*, 449-463, doi:10.1016/j.molcel.2011.06.011. 652
653
654
74. Moen, I.N.; Westhryn, M.; Håland, E.; Haug, M.; Nonstad, U.; Klaharn, M.; Standal, T.; Starheim, K.K. Smac-mimetics reduce numbers and viability of human osteoclasts. *Cell Death Discov* **2021**, *7*, 36, doi:10.1038/s41420-021-00415-1. 655
656
75. Zhang, J.; Webster, J.D.; Dugger, D.L.; Goncharov, T.; Roose-Girma, M.; Hung, J.; Kwon, Y.C.; Vucic, D.; Newton, K.; Dixit, V.M. Ubiquitin Ligases cIAP1 and cIAP2 Limit Cell Death to Prevent Inflammation. *Cell Rep* **2019**, *27*, 2679-2689.e2673, doi:10.1016/j.celrep.2019.04.111. 657
658
659
76. Anderton, H.; Rickard, J.A.; Varigos, G.A.; Lalaoui, N.; Silke, J. Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin Inflammation. *J Invest Dermatol* **2017**, *137*, 2371-2379, doi:10.1016/j.jid.2017.05.031. 660
661

77. Lawlor, K.E.; Feltham, R.; Yabal, M.; Conos, S.A.; Chen, K.W.; Ziehe, S.; Graß, C.; Zhan, Y.; Nguyen, T.A.; Hall, C.; et al. XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1 β Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation. *Cell Rep* **2017**, *20*, 668-682, doi:10.1016/j.celrep.2017.06.073. 662-664
78. Ea, C.K.; Deng, L.; Xia, Z.P.; Pineda, G.; Chen, Z.J. Activation of IKK by TNF α requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. *Mol Cell* **2006**, *22*, 245-257, doi:10.1016/j.molcel.2006.03.026. 665-666
79. O'Donnell, M.A.; Legarda-Addison, D.; Skountzos, P.; Yeh, W.C.; Ting, A.T. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. *Current biology : CB* **2007**, *17*, 418-424, doi:10.1016/j.cub.2007.01.027. 667-668
80. Dynek, J.N.; Goncharov, T.; Dueber, E.C.; Fedorova, A.V.; Izrael-Tomasevic, A.; Phu, L.; Helgason, E.; Fairbrother, W.J.; Deshayes, K.; Kirkpatrick, D.S.; et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. *The EMBO journal* **2010**, *29*, 4198-4209, doi:10.1038/emboj.2010.300. 669-671
81. Vince, J.E.; Wong, W.W.; Gentle, I.; Lawlor, K.E.; Allam, R.; O'Reilly, L.; Mason, K.; Gross, O.; Ma, S.; Guarda, G.; et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. *Immunity* **2012**, *36*, 215-227, doi:10.1016/j.immuni.2012.01.012 S1074-7613(12)00050-7 [pii]. 672-674
82. Tang, E.D.; Wang, C.Y.; Xiong, Y.; Guan, K.L. A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. *J Biol Chem* **2003**, *278*, 37297-37305, doi:10.1074/jbc.M303389200. 675-677
83. Borghi, A.; Haegman, M.; Fischer, R.; Carpentier, I.; Bertrand, M.J.M.; Libert, C.; Afonina, I.S.; Beyaert, R. The E3 ubiquitin ligases HOIP and cIAP1 are recruited to the TNFR2 signaling complex and mediate TNFR2-induced canonical NF-kB signaling. *Biochem Pharmacol* **2018**, *153*, 292-298, doi:10.1016/j.bcp.2018.01.039. 678-680
84. Varfolomeev, E.; Blankenship, J.W.; Wayson, S.M.; Fedorova, A.V.; Kayagaki, N.; Garg, P.; Zobel, K.; Dynek, J.N.; Elliott, L.O.; Wallweber, H.J.; et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell* **2007**, *131*, 669-681. 681-683
85. Zarnegar, B.J.; Wang, Y.; Mahoney, D.J.; Dempsey, P.W.; Cheung, H.H.; He, J.; Shiba, T.; Yang, X.; Yeh, W.C.; Mak, T.W.; et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. *Nature immunology* **2008**, *9*, 1371-1378, doi:10.1038/ni.1676. 684-686
86. Sun, S.C. Non-canonical NF-kB signaling pathway. *Cell Res* **2011**, *21*, 71-85, doi:10.1038/cr.2010.177. 687
87. Matsuzawa, A.; Tseng, P.H.; Vallabhapurapu, S.; Luo, J.L.; Zhang, W.; Wang, H.; Vignali, D.A.; Gallagher, E.; Karin, M. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. *Science* **2008**, *321*, 663-668, doi:10.1126/science.1157340. 688-690
88. Gardam, S.; Turner, V.M.; Anderton, H.; Limaye, S.; Basten, A.; Koentgen, F.; Vaux, D.L.; Silke, J.; Brink, R. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. *Blood* **2011**, *117*, 4041-4051, doi:10.1182/blood-2010-10-312793. 691-693
89. Varfolomeev, E.; Goncharov, T.; Maecker, H.; Zobel, K.; Komuves, L.G.; Deshayes, K.; Vucic, D. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. *Sci Signal* **2012**, *5*, ra22, doi:5/216/ra22 [pii] 10.1126/scisignal.2001878. 694-696
90. Vince, J.E.; Chau, D.; Callus, B.; Wong, W.W.; Hawkins, C.J.; Schneider, P.; McKinlay, M.; Benetatos, C.A.; Condon, S.M.; Chunduru, S.K.; et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. *J Cell Biol* **2008**, *182*, 171-184. 697-699
91. Hatem, J.; Schrank-Hacker, A.M.; Watt, C.D.; Morrissette, J.J.; Rubin, A.I.; Kim, E.J.; Nasta, S.D.; Wasik, M.A.; Bogusz, A.M. Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. *Diagn Pathol* **2016**, *11*, 137, doi:10.1186/s13000-016-0588-x. 700-702

92. Rosebeck, S.; Lim, M.S.; Elenitoba-Johnson, K.S.; McAllister-Lucas, L.M.; Lucas, P.C. API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis. *World J Biol Chem* **2016**, *7*, 128-137, doi:10.4331/wjbc.v7.i1.128.
93. Matthews, G.M.; de Matos Simoes, R.; Dhimolea, E.; Sheffer, M.; Gandolfi, S.; Dashevsky, O.; Sorrell, J.D.; Mitsiades, C.S. NF- κ B dysregulation in multiple myeloma. *Semin Cancer Biol* **2016**, *39*, 68-76, doi:10.1016/j.semcancer.2016.08.005.
94. Yang, C.; Davis, J.L.; Zeng, R.; Vora, P.; Su, X.; Collins, L.I.; Vangveravong, S.; Mach, R.H.; Piwnica-Worms, D.; Weilbaecher, K.N.; et al. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. *Cancer discovery* **2013**, *3*, 212-223, doi:10.1158/2159-8290.cd-12-0271.
95. Tseng, P.H.; Matsuzawa, A.; Zhang, W.; Mino, T.; Vignali, D.A.; Karin, M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nat Immunol* **2010**, *11*, 70-75, doi:ni.1819 [pii] 10.1038/ni.1819.
96. Xiao, Y.; Jin, J.; Chang, M.; Chang, J.H.; Hu, H.; Zhou, X.; Brittain, G.C.; Stansberg, C.; Torkildsen, Ø.; Wang, X.; et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. *Nat Med* **2013**, *19*, 595-602, doi:10.1038/nm.3111.
97. Busca, A.; Konarski, Y.; Gajanayaka, N.; O'Hara, S.; Angel, J.; Kozlowski, M.; Kumar, A. cIAP1/2-TRAF2-SHP-1-Src-MyD88 Complex Regulates Lipopolysaccharide-Induced IL-27 Production through NF- κ B Activation in Human Macrophages. *J Immunol* **2018**, *200*, 1593-1606, doi:10.4049/jimmunol.1700199.
98. Mathew, S.J.; Haubert, D.; Kronke, M.; Leptin, M. Looking beyond death: a morphogenetic role for the TNF signalling pathway. *J Cell Sci* **2009**, *122*, 1939-1946, doi:122/12/1939 [pii] 10.1242/jcs.044487.
99. Peppelenbosch, M.; Boone, E.; Jones, G.E.; van Deventer, S.J.; Haegeman, G.; Fiers, W.; Grooten, J.; Ridley, A.J. Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF. *J Immunol* **1999**, *162*, 837-845.
100. Puls, A.; Eliopoulos, A.G.; Nobes, C.D.; Bridges, T.; Young, L.S.; Hall, A. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(alpha) and IL-1, and by the Epstein-Barr virus transforming protein LMP1. *J Cell Sci* **1999**, *112* (Pt 17), 2983-2992.
101. Murali, A.; Rajalingam, K. Small Rho GTPases in the control of cell shape and mobility. *Cellular and molecular life sciences : CMLS* **2014**, *71*, 1703-1721, doi:10.1007/s00018-013-1519-6.
102. Geisbrecht, E.R.; Montell, D.J. A role for Drosophila IAP1-mediated caspase inhibition in Rac-dependent cell migration. *Cell* **2004**, *118*, 111-125.
103. Marivin, A.; Berthelet, J.; Cartier, J.; Paul, C.; Gemble, S.; Morizot, A.; Boireau, W.; Saleh, M.; Bertoglio, J.; Solary, E.; et al. cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation. *Oncogene* **2014**, *33*, 5534-5545, doi:10.1038/onc.2013.499.
104. Oberoi, T.K.; Dogan, T.; Hocking, J.C.; Scholz, R.P.; Mooz, J.; Anderson, C.L.; Karreman, C.; Meyer Zu Heringdorf, D.; Schmidt, G.; Ruonala, M.; et al. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. *Embo J* **2011**, *31*, 14-28, doi:10.1038/emboj.2011.423 emboj2011423 [pii].
105. Oberoi-Khanuja, T.K.; Rajalingam, K. Ubiquitination of Rac1 by inhibitors of apoptosis (IAPs). *Methods in molecular biology* **2014**, *1120*, 43-54, doi:10.1007/978-1-62703-791-4_4.
106. Hornburger, M.C.; Mayer, B.A.; Leonhardt, S.; Willer, E.A.; Zahler, S.; Beyerle, A.; Rajalingam, K.; Vollmar, A.M.; Furst, R. A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **2014**, *28*, 1938-1946, doi:10.1096/fj.13-235754.

107. Murali, A.; Shin, J.; Yurugi, H.; Krishnan, A.; Akutsu, M.; Carpy, A.; Macek, B.; Rajalingam, K. Ubiquitin-dependent regulation of Cdc42 by XIAP. *Cell Death Dis* **2017**, *8*, e2900, doi:10.1038/cddis.2017.305. 744
745
108. Dubrez, L.; Rajalingam, K. IAPs and cell migration. *Semin Cell Dev Biol* **2015**, *39*, 124-131, doi:10.1016/j.semcdb.2015.02.015. 746
109. Cartier, J.; Berthelet, J.; Marivin, A.; Gemble, S.; Edmond, V.; Plenchette, S.; Lagrange, B.; Hammann, A.; Dupoux, A.; Delva, L.; et al. Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription. *Journal of Biological Chemistry* **2011**, *286*, 26406-26417, doi:DOI 10.1074/jbc.M110.191239. 747
748
749
110. Glorian, V.; Allègre, J.; Berthelet, J.; Dumetier, B.; Boutanquoi, P.M.; Droin, N.; Kayaci, C.; Cartier, J.; Gemble, S.; Marcion, G.; et al. DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues. *Cell Death Dis* **2017**, *8*, e2816, doi:10.1038/cddis.2017.222. 750
751
752
111. El Hokayem, J.; Brittain, G.C.; Nawaz, Z.; Bethea, J.R. Tumor Necrosis Factor Receptor Associated Factors (TRAFs) 2 and 3 Form a Transcriptional Complex with Phospho-RNA Polymerase II and p65 in CD40 Ligand Activated Neuro2a Cells. *Mol Neurobiol* **2017**, *54*, 1301-1313, doi:10.1007/s12035-016-9742-4. 753
754
755
112. Chen, S.M.; Lin, T.K.; Tseng, Y.Y.; Tu, C.H.; Lui, T.N.; Huang, S.F.; Hsieh, L.L.; Li, Y.Y. Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21. *Cancer Med* **2018**, *7*, 3988-4003, doi:10.1002/cam4.1658. 756
757
758
113. Jin, H.S.; Park, H.S.; Shin, J.H.; Kim, D.H.; Jun, S.H.; Lee, C.J.; Lee, T.H. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. *Biochem Biophys Res Commun* **2011**, *412*, 454-459, doi:S0006-291X(11)01361-1 [pii] 10.1016/j.bbrc.2011.07.117. 759
760
761
114. Seo, T.W.; Lee, Y.T.; Lee, J.S.; Yoo, S.J. Stabilization of C-terminal binding protein 2 by cellular inhibitor of apoptosis protein 1 via BIR domains without E3 ligase activity. *Biochem Biophys Res Commun* **2020**, *530*, 440-447, doi:10.1016/j.bbrc.2020.05.098. 762
763
115. Sweeney, M.C.; Wang, X.; Park, J.; Liu, Y.; Pei, D. Determination of the sequence specificity of XIAP BIR domains by screening a combinatorial peptide library. *Biochemistry* **2006**, *45*, 14740-14748, doi:10.1021/bi061782x. 764
765
116. He, W.; Wang, Q.; Srinivasan, B.; Xu, J.; Padilla, M.T.; Li, Z.; Wang, X.; Liu, Y.; Gou, X.; Shen, H.M.; et al. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. *Oncogene* **2014**, *33*, 3004-3013, doi:10.1038/onc.2013.256. 766
767
768
117. Lee, S.; Lee, J.Y.; Lee, E.W.; Park, S.; Kang, D.H.; Min, C.; Lee, D.J.; Kang, D.; Song, J.; Kwon, J.; et al. Absence of Cytosolic 2-Cys Prx Subtypes I and II Exacerbates TNF- α -Induced Apoptosis via Different Routes. *Cell Rep* **2019**, *26*, 2194-2211.e2196, doi:10.1016/j.celrep.2019.01.081. 769
770
771
118. Romagny, S.; Bouaouiche, S.; Lucchi, G.; Ducoroy, P.; Bertoldo, J.B.; Terenzi, H.; Bettaieb, A.; Plenchette, S. S-Nitrosylation of cIAP1 Switches Cancer Cell Fate from TNF α /TNFR1-Mediated Cell Survival to Cell Death. *Cancer Res* **2018**, *78*, 1948-1957, doi:10.1158/0008-5472.CAN-17-2078. 772
773
774
775